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The outbreak of HIV infection introduced a new phenomenon in varicella zoster virus (VZV) 
pathology, namely the long-standing wart-like skin lesions that are frequently associated with 
resistance to thymidine kinase (TK)-dependent antiviral agents. This paper reviews the clinical, 
histological, and molecular aspects and the therapeutic management of these verrucous lesions. The 
majority of lesions are characterized by chronically evolving, unique or multiple wart-like cutaneous 
lesions. The main histo-pathological features include hyperkeratosis, verruciform acanthosis and VZV-
induced cytopathic changes with scant or absent cytolysis of infected keratinocytes. The mechanism 
that establishes the chronic nature of the lesions appears to be associated with a particular pattern of 
VZV gene expression exhibiting reduced or nondetectable gE and gB synthesis. Drug resistance to TK-
dependent antiviral agents is a result of nonfunctional or deficient viral TK. This necessitates 





The varicella-zoster virus (VZV) is the infectious agent responsible for chickenpox and shingles.
1
 
Following initial contact with the upper respiratory tract and/or the conjunctiva and two successive 
viremic phases, the VZV virus produces the characteristic varicella eruption. Subsequently, it 
establishes a latent infection in dorsal root ganglia. Years later, VZV can reactivate and follow an 
antidromic axonal return from the dorsal root ganglia to the skin where herpes zoster develops in the 
corresponding dermatome(s).
2,3 
As it is prone to cutaneous and/or visceral dissemination in the immunocompromised population, the 
virus is associated with a marked rate of morbidity and mortal-ity.
4–6
 The same agent is also capable of 
producing atypical cutaneous lesions and the spectrum of new skin manifestations is expanding.
7
 
Besides the hyperkeratotic VZV skin lesions that represent the most frequently encountered atypical 
phenomenon, lichenoid reactions
8,9
 and follicular herpes zoster
10–12
 have recently been described. 
In the 1980s, the first reports of long-standing or chronic VZV infections appeared.
4,13
 Precise data 
regarding the incidence and prevalence of such lesions in HIV-infected patients and in organ transplant 
recipients are not available. However, due to their atypical features, they probably remain quite 
frequently unrecognized. Currently, the majority of the cases are found in HIV-infected patients with 
low CD4 cell counts; however, cases have occasionally been observed in organ transplant recipients.
14–
30
 In general, the lesions the most florid and characteristic in patients with low CD4 cell counts. 
Because the administration of triple therapy for AIDS prevents the occurrence of low CD4 cell counts, 
the recognition of these lesions may become even less certain. 
Chronic verrucous lesions differ from stereotypic varicella and herpes zoster lesions in many aspects. 
In addition to their atypical clinical manifestations, different diagnostic methods may be required, the 
histopathological features are heterogenous, and the pathogenesis of the lesion is peculiar. The 







Published in : Clinical and experimental dermatology (1999), vol. 24, iss. 5, pp. 346-353 
Status : Postprint (Author’s version) 
 
The vast majority of verrucous VZV occurs in HIV-infected patients with low CD4 cell counts.
14–30
 
However, some cases have been described in patients under immunosuppressive regimens for organ 
transplanta-tion.
7
 and the entity has occurred in an immunocompe-tent patient.
36
 No particular sex ratio 
or racial predilection appears to exist. Individuals aged 4–48 years can be affected.
13–30,37–41
 Although 
there is a significant clinical polymorphism of chronic verrucous VZV lesions, the typical presentation 
consists of single or multiple pox-like or wart-like hyperkeratotic and well demarcated lesions which 
vary from 4mm to 10cm in diameter (Fig. 1).
26
 Any site of the body surface can be affected and, 




Figure 1 (a) Multiple verrucous VZV lesions on the dorsum of the hand. (b) Single verrucous VZV 




The lesions usually persist from several weeks to months and present periods of extension or regression 
without healing completely.
14–30
 In some cases, the hyperkeratosis vanishes and chronic, indolent and 
necrotic ulcerations manifest.
13,20,26
 Verrucous zoster responsive to antiviral treatment usually clears in 
about 2–3 weeks. Atrophic, varicella-like scarring may occur after healing. Relapses of verrucous 
lesions after successful therapy are possible and may affect either the same or another site. 
In these immunosuppressed patients, several clinical situations can preceed the development of chronic 
VZV verrucous lesions. Initially, verrucous lesions can follow varicella, particularly in children.
26,42
 In 
this instance, the varicella skin lesions show no tendency towards healing and progressively take on a 
wart-like appearance. 
Secondly, verrucous lesions can develop directly from shingles.
14–30
 These predominantly adult patients 
suffer a zosteriform eruption that does not resolve but slowly progresses to hyperkeratotic nodules. 
Thirdly, the lesions can occur in subjects showing no evidence of classic herpes zoster
20
 and are 
probably derived from haematogenous dissemination after dorsal root ganglia reactivation without 
dermatomal involvement. 
The clinical differential diagnosis includes molluscum contagiosum,
30,42
 basal cell carcinoma
14
 and 
occasionally the lesions may resemble ecthyma gangrenosum or disseminated deep fungal infection. 
Chronic VZV infection may also affect extracutaneous sites, causing chronic myelitis without 
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Like the clinical presentation, the histopathological features of chronic verrucous zoster are often 
hetero-genous (Fig. 2).
22,45
 However, the typical wart-like lesions are basically similar and they are 
characterized by a massive orthokeratotic hyperkeratosis, sometimes accompanied by the presence of 
parakeratotic columns. The epidermis exhibits varying degrees of papillomatous verrucous, sometimes 
even pseudo-epitheliomatous hyperplasia.
21,22
 The papillomatosis extends into the papillary dermis and 
even deeper into the reticular dermis. Occasionally, the adnexal structures also participate in the 
epithelial hyperplasia. 
A variable degree of viral cytopathic changes are observed. The nuclear changes include the presence 
of multiple steel-grey appearing nuclei and Cowdry type A nuclear inclusions. Necrotic keratinocytes 





Figure 2 Histological appearance of a verrucous VZV lesion (x 200). 
 
 
This latter feature is at variance with classic VZV infection in keratinocytes where cytolysis is a 
principal feature.
10,45
 These alterations are observed most frequently in the granular layer. 
In some lesions, signs of alpha-herpesviridae-induced histopathological changes are not observed and 
the diagnosis can easily be overlooked. In the absence of viral cytopathic changes, keratoacanthoma 
and verru-cous carcinoma should be ruled out. 
An inflammatory response of neutrophils and lymphocytes infiltrating the dermis and/or the 
hyperplastic epidermis is occasionally observed; however, in the majority of cases there is a lack, or 





VZV has been determined as the sole pathogenic agent in chronic verrucous lesions.
14–28,45
 The 
presence of other DNA viruses, such as poxviruses, herpes simplex virus (HSV), Epstein–Barr virus or 
cytomegalovirus in chronic verrucous lesions, has previously suggested that this manifestation is not 
virus-specific.
29
 However, as the reports of VZV-associated cases greatly outnumber those of other 
viruses, and as the features are clearly distinctive, the majority of authors favour the hypothesis that it 
is a typical VZV-associated phenomenon.
14–28,45  
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Figure 3 IE63 immunostaining in the nucleus of infected keratinocytes of a verrucous lesion 
(polyclonal anti-IE63 antibody, 1/250) (x 200).47 
 
 
A possible coinfection with human papillomaviruses, suspected by the hyperkeratotic character of the 
lesions, has been ruled out.
22 
In AIDS patients, VZV skin infections may vary from verrucous lesions, in which viral synthesis 
appears to be strongly attenuated or even absent,
45
 to full-blown viral replication represented clinically 
by herpes zoster or chickenpox lesions. Hence, the clinical polymorphism and the wide spectrum of 
VZV skin manifestations might depend upon a particular pattern of VZV gene expression which can 
vary in concert with fluctuations in the immune status seen in AIDS patients. However, the exact 
influence of the host defence system in the pathogenesis of verrucous zoster is not clear, as the 





 and AIDS patients.
14–29 
The VZV replicative cycle is organized in a cascade involving three successive phases, namely the 
immediate-early (IE), early (E), and late (L) stages.
1,3
 After the attachment of the virus to the host cell 
membrane, the nucleocapsid is released into the host cell cytoplasm as well as proteins from the 
tegumentum lying between nucleocapsid and envelope. These proteins migrate to the nucleus along 
with the viral DNA released from the nucleocapsid and trigger the first phase of viral transcription. 
During the IE phase, IE genes are expressed and IE proteins are synthesized; the latter playing an 
important role in the establishment of latency in the dorsal root ganglion. Only some IE gene products, 
such as IE4, IE62, and IE63, and an E gene product called major DNA binding protein (MDBP) have 
been identified during latency in the dorsal root ganglion.
46–50
 It remains unknown which factors are 
responsible for maintaining the virus in the latent state, or activating its complete replicative cycle. 
In the early phase, E proteins, such as MDBP, DNA-polymerase and thymidine kinase (TK) are 
produced. The E gene products play key roles in the synthesis of new viral DNA. 
During the late phase, L proteins, such as the viral envelope glycoproteins gE, gB, gC, gD, gH and gI, 
are synthesized.
1
 Subsequently, the newly formed nucleo-capsids become enveloped particles at the 
level of the cell nuclear membrane and are transported to the plasma membrane in large vacuoles 
where they are released from the cell by reverse phagocytosis. 
In the usual VZV infection of keratinocytes, IE, E, and L gene products are abundantly synthesized. 
These infected cells display typical cytopathic changes.
45
 The intensity of viral replication probably 
plays a role in host cell death. In addition, recent in vitro
51
 and in vivo (unpublished results) data also 
favour the involvement of apoptosis. 
The altered immune environment possibly creates a different relationship between the keratinocyte and 
VZV, leading to aberrant gene expression such as absent or changed viral TK synthesis (see 
Mechanisms of drug resistance) and/or reduced or undetectable L protein synthesis. Whether these 
different expression patterns are invariably associated or individually regulated remains unknown. 
The pathogenesis of the chronic course and the near absence of cytolysis in verrucous VZV lesions 
remains unclear. An absent or reduced synthesis of L proteins gB and gE was found in noncytolytic 
keratinocytes using semiquantative immunohistochemical assessment of chonic verrucous VZV lesions 
in AIDS patients.
45
 In contrast, a strong immunohistochemical signal for the IE63 gene product could 
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be demonstrated in all lesions (Fig. 3). It has been postulated that a decreased level of viral synthesis 
enables the host cell to survive and that a nonpermissive, chronic viral infection is established. 
Another histological characteristic of verrucous zoster is the near absence of inflammatory infiltrate. 
Considering the prominent immunogenic properties of the envelope proteins gE and gB, it is 
conceivable that the paucity or absence of these major immunogenic glyco-proteins on the host cell 
membrane limits MHC class I-associated antigen presentation to the CD8 cytotoxic immune system 
which is already impaired in AIDS patients. Another mechanism that assists the virus to evade the host 
immune response may be inhibition of MHC class I antigen expression.
52
 The silencing of host cell 
immune responsiveness together with the reduced level of viral synthesis is a plausible explanation for 
the chronicity of the lesions. 
The other alpha-herpesviruses, HSV 1 and HSV 2, are also capable of causing chronic cutaneous 
infections.
53–55 
There is, however, only one single case report that matches the clinical and histological 
features of chronic VZV verrucous lesions.
56
 Extracutaneous chronic disease, such as a HSV chronic 
laryngitis in an AIDS patient
57 
and chronic meningitis due to HSV in an immunocom-petent host
58
 has 
been reported. As with VZV verrucous lesions, the precise intervention of the immune system in the 
developmentofthe HSV chronic lesions,asdescribed in immunocompetent
58
 and immunosuppressed 
patients,
57 
is not clear. Although unproven, the pathogenic mechanisms of chronic HSV skin lesions 
and of extra-cutaneous chronic VZV and HSV lesions could be similar to those proposed for cutaneous 







The diagnosis of the hyperkeratotic VZV lesions is rooted in the recognition of the above-described 
histopathologi-cal features from a skin biopsy. Although most of the cases are associated with the VZV 
virus, HSV type 1 or 2 infection shouldberuled out using immunohistochemistry or in situ 
hybridization. These methods are also mandatory to prove the viral origin when histopathological signs 
of VZV cytopathology are absent. As altered viral gene expression may be observed, 
immunohistochemical screening for VZV should preferentially include antibodies directed against 






In viral culture from clinical specimens, VZV is more difficult to recover than HSV. Furthermore, viral 
culture is of little use as a rapid diagnostic tool. TK-deficient VZV strains, frequently observed in 
chronic verrucous lesions, are known to be even more challenging to grow in culture. On the other 
hand, the hyperkeratotic character of the lesions does not easily permit sampling for culture. Hence 
viral culture is not the ideal diagnostic tool with which to identify VZV in these lesions. However, 






Due to the difficulty of sampling, the Tzanck smear is not a useful diagnostic tool in the presence of 
hyperkeratotic lesions. However, in ulcerated lesions, an immunohisto-chemically based differential 
diagnosis can be obtained from a smear.
60
 Again, the indolent and nonflorid character of the lesions do 





Intranuclear viral particles consistent with VZV infection in keratinocytes have been identified by 
electron micro-scopy.
21,22,61,62
 As distinction between VZV and HSV is not possible by ultrastructural 
morphology, electron microscopy should be considered only as a complementary diagnostic aid. 
 
 
Mechanisms of drug resistance 
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Relapse of VZV infection in AIDS patients that requires frequent, long-term maintenance, and often 
low-dose, suppressive acyclovir (ACV) treatment,
63







verrucous zoster is frequently associated with ACV-resistance.
20,37,62
 The mutations leading to 
resistance are located at the level of the viral TK, a 35-kDa protein with both thymidine and 
thymidylate phosphorylating properties. It possesses an overall sequence identity of ≈ 28% with HSV 
TK. 
To be active, ACV must be phosphorylated three times. The viral TK is responsible for the first 
phosphorylation of ACV and the two subsequent phosphorylations are performed by TK encoded by 
the host cell. Sequencing of the TK gene of drug resistant VZV strains has revealed nucleotide 
deletions or insertions that introduce a premature termination codon; this probably leads to the 
synthesis of a truncated, nonfunctional TK protein. These may occur at various positions in the protein, 
such as in the conserved nucleotide (ATP) binding site, in the nucleoside (substrate) binding site, 
between the binding sites and at the C-terminal end of the protein.
69
 These alterations lead to loss of 
enzymatic activity and confer resistance to TK-dependent drugs. Cross-resistance between TK-
dependent drugs such as ACV, penciclovir, 882C and BV-ara-U in in vitro drug susceptibility assays 
occurs in most instances, but when resistance is suspected clinically, the use of another TK-dependent 
drug may be considered. 
Occasionally, changes in the DNA polymerase gene are observed, conferring resistance to DNA 
polymerase inhibitors such as phosphoformic acid (foscarnet, PFA) and vidarabine. As for TK-
dependent drugs, cross-resistance between DNA polymerase inhibitors is not always found: this is 
illustrated by successful intravenous PFA treatment (40 mg/kg per 8 h for 7 days) in progressive 
vidarabine-resistant (10 mg/kg per day), ACV-resis-tant HSV infection in a patient with AIDS.
70
 
However, clinical resistance to PFA (6–to 15 g per day, i.v.) associated with in vitro PFA resistance has 






The therapeutic approach to verrucous VZV lesions differs from the management of usual VZV 
infections in the immunocompromised population,
63
 especially due to the problem of TK-dependent 
drug resistance.   
First, it is important to consider that in vitro drug susceptibility testing cannot always predict clinical 
responses. In five cases of ACV-resistant VZV infections treated with PFA, the clinical results were 
not predicted by drug susceptibilty testing. In fact, the authors observed healing despite the presence of 
PFA resistant 
VZV strains and clinical failure although in vitro suscep-tibilty to PFA was observed.
66
 Drug 
susceptibilty testing also remains a time-consuming procedure and the majority of the therapeutic 
decisions have to be taken without test results. 
Another important point to consider is that the drug-resistance of virus isolated from one given lesion 
may vary over time. Initially TK-deficient VZV strains can be isolated from hyperkeratotic lesions; 
after some time, however, samples from the same clinical lesions may produce functional TK proteins 
in viral culture. Hence, initial drug failure does not necessarily imply that this drug should be 
eliminated from the alternative therapeutic options. 
Once diagnosed, intravenous or oral ACV is the first-line treatment at a dose of 30 mg/kg per day for 
10 days; however, longer treatment is frequently required to achieve any response. When ACV-
resistance is suspected clinically, several therapeutic alternatives can be considered. A patient already 
treated with suppressive ACV doses could benefit from higher oral ACV dosages, or a change to the 
intravenous formulation of ACV (10 mg/kg per 8 h); poor intestinal absorption of ACV should 
therefore be considered in the event of therapeutic failure. Another possibility is to use the newer oral 
formulations such as valaciclovir (3 x 1000mg/day) that achieve a higher oral bioavailability than oral 
ACV, or oral famciclovir (3 x 500 mg/day) that converts to penciclovir. 
If increasing doses of a drug fail to produce clinical improvement after ≈ 1 week, intravenous PFA 
(40– 60mg/kgper 8 h)for 7-10 days may be attempted. , , As cross-resistance between TK-dependent 
drugs is not automatic, the use of oral famciclovir (3 x 500 mg/day) could be considered as third 
therapeutic alternative in the case of a clinical suspicion of an ACV-resistant VZV strain. 
Combining intravenous or oral ACV and PFA possibly remains the most reasonable treatment 
approach from a theoretical point of view. A successful outcome after 5 weeks with a combined 
treatment of intralesional interferon α-2b (twice weekly) and topical 1% trifluorothy-midine solution 
(four times daily) has been described in a patient with ACV-resistant herpes zoster. Another treatment 
option in the event of suspected TK-dependent drug resistance consists of topical administration of the 
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acyclic nucleoside phosphonate analogue cidofovir. , A73209 (Lobucavir) is an oral drug of the 
oxetanocin family of cyclobutyl nucleoside analogues. As its activity against TK-negative VZV strains 
is much lower than that against TK-positive strains
76
 it represents no practical therapeutic alternative in 
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